Bi­par­ti­san group of law­mak­ers seeks to reign in phar­ma patent thick­ets with new bill

Sen­a­tors on both sides of the aisle are seek­ing to ease mar­ket en­try for gener­ics and biosim­i­lars with a new bill that would cre­ate guardrails around patent thick­ets, or a con­glom­er­a­tion of patents that cov­er a sin­gle prod­uct and were most fa­mous­ly used to ex­tend the mo­nop­oly of Ab­b­Vie’s block­buster Hu­mi­ra (adal­i­mum­ab).

The leg­is­la­tion would re­strict the num­ber of patents com­pa­nies can as­sert in lit­i­ga­tion. It would al­so pro­hib­it patent own­ers from as­sert­ing more than one patent from the same patent group in sep­a­rate ac­tions against the same al­leged in­fringer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER